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Abstract Molecular balance between Angiopoietin-1
(Ang-1) and Angiopoietin-2 (Ang-2) has important effects
in tumor angiogenesis. Ang-2 was shown to be elevated
and proved to be a prognostic factor in acute myeloid
leukemia (AML). To date studies revealed increased an-
giogenesis in bone marrows (BMs) of both myeloprolif-
erative neoplasm (MPN) and AML patients. We conducted
this study to demonstrate circulating levels of Ang-1 and
Ang-2 in MPN patients since no data exists in literature.
Thirty-three newly diagnosed MPN, 27 newly diagnosed
AML patients and 25 controls (HC) were enrolled and
Angiopoietin levels were determined with ELISA. We
found that Ang-1 levels were higher whereas Ang-2 levels
were lower in MPN and HC when compared to AML. Our
results suggest that though angiogenesis is increased in
both AML and MPN, angiopoietin serum level profile of
the two diseases are different, and MPN patients have
similar Ang-1 and Ang-2 levels as HC. We conclude that,
according to our results Ang-1 and Ang-2 do not only
regulate tumor angiogenesis and the difference between
angiopoietin levels of acute and chronic myeloid neo-
plasms could be a reflection of other effects of these growth
factors on tumor malignancy.
Keywords Angiopoietin-1  Angiopoietin-2 
Angiogenesis  Myeloproliferative neoplasm  Acute
myeloid leukemia
Introduction
Malignant tumors are characterized by uncontrolled pro-
liferation and metastasis to distant locations [1]. Angio-
genesis has an important role in the growth, dissemination,
and metastatic capacity of solid tumors [2]. However, it has
also been shown that it may have a crucial pathophysio-
logic role in the development of hematologic malignancies
[3]. Increased microvessel density (MVD) has been
demonstrated in many hematologic disorders, such as acute
and chronic leukemia, myelodysplastic syndrome, multiple
myeloma and MPN [3–5]. Studies show that MVD is sig-
nificantly increased in patients with newly diagnosed acute
myeloid leukemia (AML) compared with control subjects,
and returns to a normal level after complete remission (CR)
is achieved [6, 7]. In literature, there are several studies
demonstrating an increase in angiogenesis in myeloprolif-
erative neoplasms (MPN) [3, 8, 9]. The article studying
vascular density in BM samples of patients with MPN,
revealed increased vascularity in polycythemia vera (PV),
chronic myeloid leukemia (CML) and primary myelofi-
brosis (PMF) patients [4]. Alonci et al. demonstrated that
serum VEGF levels were increased in MPN patients when
compared to controls [8]. In the study conducted by Mu-
solino et al. in which only CML and essential thrombo-
cythemia (ET) patients were included, serum Angiogenin,
another angiopoietic factor, was found to be increased in
the patient group when compared to controls [10].
VEGF and the angiopoietins are among the most im-
portant growth factors in the tumor ecosystem.
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Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) and
their Tie2 receptor tyrosine kinase have wide-ranging ef-
fects on tumor malignancy that includes angiogenesis, in-
flammation, and vascular extravasation. The regulatory
role of Ang-1 and Ang-2 in tumor angiogenesis remains
controversial due to the conflicting roles of both an-
giopoietins in angiogenesis [11]. Ang-1 activates Tie2
more strongly than does Ang-2; thus, some of the effects of
Ang-2 could result from the inhibition of Ang-1 signaling
[1, 12]. Ang-1–Tie2 signaling is thought to limit angio-
genesis in mature vessels [1].
Ang-1, Ang-2 and Tie2 levels have been extensively
studied in AML patients [12–15]. According to the results,
Ang-2 was found to be elevated in AML patients as
compared to controls and Ang-2 was proved to be an in-
dependent prognostic factor in AML [13]. To our knowl-
edge, till now no data about circulating levels of Ang-1 and
Ang-2 in MPN patients exists in literature. We decided to
conduct this study in order to demonstrate serum levels of
Ang-1 and Ang-2 in Ph(-) MPN patients and compare
their serum level profiles both with AML patients and HC.
Materials and Methods
Thirty-three newly diagnosed Ph(-) MPN patients (13 ET,
16 PV, 4 PMF) and 27 newly diagnosed AML patients who
admitted to Hematology Department from January 2011 to
August 2012 were enrolled to this study. Twenty-five
healthy individuals were included as the healthy control
group. ET, PV and PMF patients were diagnosed according
to 2008 World Health Organization (WHO) diagnostic
criteria for MPNs [16]. AML patients were diagnosed ac-
cording to 2008 WHO classification of acute leukemia
[17]. Healthy controls were age and sex matched with the
patient groups and they had no diagnosed disease which
could interfere with the results of the study. Characteristics
of MPN, AML patients and HC are shown in Table 1.
Blood samples were collected from both the MPN and
AML patients at the time of diagnosis before the initiation
of therapy. Complete blood cell counts, biochemical test
results of patients and HC were registered. Besides,
splenomegaly (SM) and JAK2 V617F mutation status of
MPN patients and cytogenetics of AML patients were also
registered. However, in 40 % of in AML patients cytoge-
netic analysis results were undetermined due to a low
number of metaphases (\20 metaphases). Characteristics
of AML patients are shown in Table 2. After the samples
were taken for the study, all of the AML patients received
3 ? 7 remission induction therapy (Idarubicin 12 mg/m2,
3 days ? Ara-C 100 mg/m2, 7 days). Patients who have
normal complete blood counts and have a normocellular
marrow and \5 % blasts in BM examination after the
induction therapy were accepted as in CR. Patients who
were in CR, received four courses of consolidation therapy
with high-dose Ara-C (3 g/m2 every 12 h, 3 days). Patients
who were refractory to therapy or relapsed received FLAG
[Fluda-rabine (30 mg/m2, days 1–5), Ara-C (1 g/m2, over
3 h every 12 h, days 1–5) and G-CSF (5 lg/kg/day sub-
cutaneously from day 0 until the white blood count was
[20 9 109/l)] chemotherapy. Relapsed or refractory pa-
tients who were eligible for hematopoietic stem cell
transplantation (HSCT) received HLA-identical, unrelated
or haploidentical allogeneic transplantation. Samples col-
lected from patients and HC were immediately centrifuged
and the sera were stored at -80 C. Serum Ang-1and Ang-
2 levels were measured by commercial ELISA kits (ANG-
2:R&D Systems, USA, ANG-1:RayBiotech Inc.,USA).
The minimum detectable dose of Ang-1 was less than
30 pg/ml. While, intra-assay CV was\10 %, inter-assay
CV was\12 % for Ang-1 ELISA kit. The minimum de-
tectable dose of Ang-2 was 8.29 pg/mL. Intra-assay CV
was 4.2–6.9 % and inter-assay CV was 7.4–10.4 % for
Ang-2 ELISA kit. Only single measurement were per-
formed for each sample. The study was approved by the
Faculty Research Ethical Committee and informed con-
sents from both the patients and healthy controls were
taken.
SPSS 21.0 (IBM Statistics SPSS, USA) software was
used for statistical analyses. Comparisons of non-para-
metric variables were performed with Kruskal–Wallis and
Mann–Whitney U-tests. Correlation analyses were per-
formed by using Spearman’s correlation. Survival curves
were estimated using the Kaplan–Meier method, and the
log-rank test was used to compare survival between groups.
Overall survival (OS) was the primary outcome studied and
was calculated from the date of first diagnosis to death
from any cause. Univariate and multivariate Cox propor-
tional hazards regression analyses were performed to
evaluate the predictive effect of each factor. A p value of
less than 0.05 was considered as a statistically significant
result.
Results
Serum Ang-1 levels were significantly lower in AML pa-
tients [92.68 pg/ml (22.28–1946.5)] when compared to
both MPN patients [6760.4 pg/ml (1593.6–9723.2)] and
HC [6153.4 pg/ml (1699.5–7454)] (p\ 0.0001). But there
were no statistically significant difference between Ang-1
levels of MPN patients and HC (p = 0.15) (Fig. 1). On the
other hand, serum Ang-2 levels were significantly in-
creased in AML patients [3667.1 pg/ml (1167.6–1337.5)]
when compared to both MPN patients [1263.5 pg/ml
(749.2–1013.8)] and HC [1331.1 pg/ml (791.7–8227.7)]
Indian J Hematol Blood Transfus (Apr-June 2016) 32(2):162–167 163
123
(p\ 0.0001). Similar to Ang-1 levels, there were no sta-
tistically significant difference between Ang-2 levels of
MPN patients and HC (p = 0.85) (Fig. 2).
In sub-group analysis, Ang-2 levels did not differ sig-
nificantly between ET, PV, PMF patients and HC
(p[ 0.05). While, serum Ang-1 levels of PV patients were
significantly higher in comparison to both PMF patients
and HC, Ang-1 levels of PMF patients were significantly
lower in comparison to HC (p = 0007, p = 0001,
p = 0.05, respectively).
Ang-1 and Ang-2 levels didn’t differ significantly be-
tween JAK2 mutation positive and negative MPN patients
Table 1 Characteristics of
Ph(-) MPN patients, AML
patients and HC
Ph(-) MPN AML HC p
Number of patients (%) 33 (38.8) 27 (31.7) 25 (29.5)
Age (year) median (range) 53 (31–80) 47 (22–70) 45 (25–68) 0.06*
F/M 8/25 7/20 10/15 0.38**
Hb (g/dl) median (range) 15.9 (9.38–21.2) 8.02 (4–13.5) 14.7 (12–16,8) \0.001*
Htc (%) median (range) 48.3 (28–63.3) 23.2 (10.4–40.5) 43.8 (36.6–53.2) \0.001*
WBC (10^9/L) median (range) 12 (3.2–37.9) 10 (0.6–203) 6.5 (4.7–10.9) \0.001*
Plt (10^9/L) median (range) 534 (119–1448) 44.3 (16.3–199) 279 (168–448) \0.001*
LDH (U/L) median (range) 312 (157–1341) 421(129–1767) 165 (136–334) \0.001*
Creatinine (mg/dl) median (range) 0.9 (0.53–2) 0.87 (0.59–1.75) 0.79 (0.6–1.17) 0.01*
Splenomegaly (±) 15/18 N/a N/a N/a
JAK2 V617F mutation (±) 23/10 N/a N/a N/a
F female, M male, Hb hemoglobin, Htc hematocrit, WBC white blood cell count, Plt platelet count, LDH
lactate dehydrogenase, N/a not applicable
* Kruskal–Wallis test
** Chi square test
Table 2 Characteristics of
AML patients Characteristics of
the 27 patients with acute
myeloid leukemia
Variables Number of patients (%)
Sex
Male 20 (75)
Female 7 (25)
Age (year) median (range) 47 (22–70)
WHO classification
Acute myeloid leukemia, minimally differentiated 1 (4)
Acute myeloid leukemia without maturation 10 (37)
Acute myeloid leukemia with maturation 9 (33)
Acute myelomonocytic leukemia 6 (22)
Acute monoblastic/acute monocytic leukemia 1 (4)
Karyotype*
Favourable 0 (0)
Intermediate 14 (52)
Unfavourable 2 (8)
Undetermined 11 (40)
CR after 1st remission induction therapy 13 (48)
HSCT** 5 (18)
Overall survival (months)*** 9 (1–27)
WHO world health classification, CR complete remission
* Favorable, t(8;21), inv(16); unfavourable, -7, del(7q), -5, del(5q), 3q abnormality, complex; interme-
diate, normal karyotype, and other abnormalities
** HSCT: Received allogeneic hematopoietic stem cell transplantation
*** Median (range)
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(p = 0 27, p = 0.86, p = 0.79, respectively). Likewise,
Ang-1 and Ang-2 levels were not significantly different
between MPN patients with SM and without SM.
There were no statistically significant difference be-
tween Ang-1and Ang-2 levels of female and male subjects
in any groups (p[ 0.05). No correlation could be found
between age and levels of Ang-1, Ang-2 in MPN, AML or
HC (p[ 0.05). Likewise, no correlation could be found
between LDH, leukocyte count, thrombocyte count and
levels of Ang-1, Ang-2 in MPN, AML patients or HC
(p[ 0.05).
When Ang-1and Ang-2 levels of AML patients who are
in CR after induction therapy (13 patients) and who are
refractory to induction therapy analysed, baseline Ang-2
levels were found to be significantly higher in non-re-
sponders (p = 0.03). However, there were no significant
Fig. 1 Serum Ang-1 levels in
Ph(-) MPN patients, AML
patients and HC
Fig. 2 Serum Ang-2 levels in
Ph(-) MPN patients, AML
patients and HC
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difference in responder and non-responder patients in terms
of baseline Ang-1 levels (p[ 0.05). In survival analysis,
AML patients were divided into a low group (expression of
angiogenic factor below the median) and a high group
(above the median). Univariate analysis of factors associ-
ated with OS showed a significantly shorter survival in the
patients with higher Ang-2 level (p = 0.020; Fig. 3).
However, Ang-1 levels didn’t have any impact on survival
(p = 0.588).
Discussion
The role of angiogenesis in solid tumors is well-established
and there is also growing evidence about the role of an-
giogenesis in hematological malignancies [3, 4, 15]. In
literature, there are several studies demonstrating an in-
crease in angiogenesis in MPN and AML [3, 6, 8]. In our
study, we determined serum Ang-1 levels were sig-
nificantly lower, whereas serum Ang-2 levels were sig-
nificantly higher in AML patients when compared to both
MPN patients and HC. However, no significant difference
in terms of serum Ang-1 or Ang-2 levels between MPN
patients and HC existed. In sub-group analysis, Ang-1
levels of PMF patients were significantly lower in com-
parison to HC, similar to AML patients. This could be the
result of inadequate number of PMF patients in our study
or could be due to the higher probability of leukemic
transformation feature of PMF.
To our knowledge, no data exists so far on blood levels
of serum Ang-1 in MPN patients. There is only an article in
literature demonstrating differential levels of soluble Ang-
2 and Tie2 in patients with hematological malignancies, in
which 25 ET patients were also enrolled. In this study,
Ang-2 levels of ET patients were not significantly different
from controls, similar to our study [18]. Our results suggest
that, though there were several studies in literature
demonstrating increased angiogenesis in MPN patients,
Ang-1 and Ang-2 levels were not different from healthy
controls.
In our study, Ang-1 and Ang-2 levels didn’t differ sig-
nificantly between JAK2V617F mutation positive and
negative MPN patients. This finding was in accordance
with the literature. A study revealed that there was no as-
sociation between JAK2-V617F mutational status and
MVD and VEGF-expression in BM of MPN patients [19].
In the AML group of our study, we determined Ang-2
levels of AML patients significantly higher compared to
HC and MPN patients. Baseline Ang-2 levels were found
to be significantly higher in non-responder patients to in-
duction chemotherapy when compared to responders.
Moreover, OS of the AML patients with higher Ang-2
levels were shorter. In literature, there are several studies
demonstrating the prognostic role of Ang-2 in AML pa-
tients. In a study, the authors have investigated the ex-
pression of Ang-1, Ang-2, Tie2, VEGF-A, and VEGF-C
genes in BM mononuclear cells in newly diagnosed de
novo AML and normal marrow donors. This study revealed
that high pre-treatment levels of Ang-2 in the BM indicate
an unfavorable prognosis in AML and it is an independent
prognostic factors for overall survival [15]. In another
study, marrow levels of Ang-1, Ang-2, and Tie2 were de-
termined using ELISA in AML patients before che-
motherapy and controls, revealing higher levels of Ang-2,
Tie2 and lower levels of Ang-1 in AML patients. More-
over, patients with lower Tie2 and Ang-2 levels had a
survival advantage [12].
There were no studies in literature comparing serum
angiopoietin level profiles of AML and MPN patients in
literature. Our study revealed that, Ang-1 and Ang-2 levels
differ significantly between AML and MPN patients when
compared to healthy controls. Mazzieri et al. revealed that
Ang-2-Tie2 axis mediates cell-to-cell interactions between
Tie2-expressing macrophages and endothelial cells that are
important for tumor angiogenesis [20]. Although, increase
in angiogenesis is a well-known fact both in AML and
MPN, the increased tumorigenic potential in AML can be
an explanation for the difference between serum level
profiles of the two diseases. Besides, Scholz et al.
demonstrated that Ang-1 and Ang-2 have regulatory roles
Fig. 3 Kaplan–Meier curves of overall survival of AML patients
according to Ang-2 levels. AML patients with baseline Ang-2
[3667.1 pg/ml displayed significantly worse survival rates than those
with baseline Ang-2 levels\3667.1 pg/ml
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on inflammation and while, Ang-1 seems to have an anti-
inflammatory role, Ang-2 exerts a proinflammatory effect
[21, 22]. These data reveal that Ang-1 and Ang-2 not only
regulate tumour angiogenesis and there can be other factors
affecting serum levels of Ang-1 and Ang-2.
Conclusion
In conclusion, our study revealed that MPN disease pa-
tients’ serum Ang-1 and Ang-2 levels were similar to HC.
Moreover, Ang-1 and Ang-2 levels of AML patients were
significantly different from both MPN patients and HC.
Former studies revealed that Ang-1 and Ang-2 can both act
as angiogenic or anti-angiogenic. Our study revealed that
that molecular balance between Ang-1 and Ang-2 is the
same as in HC, just the opposite to AML. Similar to studies
in literature our study revealed higher Ang-2 level had a
negative impact on response to remission induction therapy
in AML patients. According to our results Ang-1 and Ang-
2 do not only regulate tumour angiogenesis and the dif-
ference between angiopoietin levels of acute and chronic
myeloid neoplasms could be a reflection of other effects of
these growth factors on tumor malignancy and should be
investigated in further more comprehensive studies.
Moreover, considering that the leukemic transformation of
myeloproliferative disorders and the significant difference
between MPN and AML patients in terms of Ang-1 and
Ang-2 levels, it may be speculated that serial measure-
ments of their levels could be used for early prediction of
leukemic transformation in MPN patients.
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